Environment-mediated drug resistance: a major contributor to minimal residual disease

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment

Background:

• Environment-mediated drug resistance is a de novo resistance mechanism protecting tumor cells from initial therapies.
• Residual disease foci can develop acquired resistance under therapeutic selective pressure.
• This resistance arises from reciprocal signaling between tumor cells and their microenvironment.

Purpose of the Study:

• To highlight the role of the tumor microenvironment in mediating drug resistance.
• To propose therapeutic strategies targeting tumor-microenvironment interactions.
• To prevent the emergence of acquired resistance during cancer therapy.

Main Methods:

• Review of recent evidence on environment-mediated drug resistance.
• Analysis of reciprocal signaling pathways between tumor cells and the microenvironment.
• Conceptual framework for therapeutic intervention.

Main Results:

• Environment-mediated drug resistance is an adaptive response involving tumor-stroma interactions.
• Targeting these interactions may offer a novel therapeutic approach.
• Early intervention is crucial to prevent the development of permanent acquired resistance.

Conclusions:

• Therapeutic strategies should target the tumor-environment dialogue.
• This approach aims to overcome de novo resistance and prevent acquired resistance.
• Targeting the tumor microenvironment is a promising strategy for enhancing cancer therapy efficacy.